Sprint Bioscience AB (OSTO:SPRINT) Accounts Payable: kr2.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
32 GF Score
Price kr3.86
GF Value kr2.18
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Sprint Bioscience AB Accounts Payable?

Sprint Bioscience AB OSTO:SPRINT +1.58% 32 Accounts Payable is kr2.4 Mil as of Mar. 2026. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Sprint Bioscience AB's Accounts Payable for the quarter that ended in Mar. 2026 was kr2.4 Mil.

Sprint Bioscience AB's quarterly Accounts Payable increased from Sep. 2025 (kr3.3 Mil) to Dec. 2025 (kr4.4 Mil) but then declined from Dec. 2025 (kr4.4 Mil) to Mar. 2026 (kr2.4 Mil).

Sprint Bioscience AB's annual Accounts Payable declined from Dec. 2023 (kr5.7 Mil) to Dec. 2024 (kr5.4 Mil) and declined from Dec. 2024 (kr5.4 Mil) to Dec. 2025 (kr4.4 Mil).

Sprint Bioscience AB Accounts Payable Related Terms

Sprint Bioscience AB Accounts Payable Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB Accounts Payable Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.92 3.73 5.71 5.44 4.40

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.43 3.81 3.30 4.40 2.40
OSTO:SPRINT
32GF Score
Sprint Bioscience AB OSTO:SPRINT
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of kr2.4 Mil mean?
Sprint Bioscience AB (OSTO:SPRINT) has a Accounts Payable of kr2.4 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sprint Bioscience AB and its competitors.
Is Sprint Bioscience AB's Accounts Payable too high?
Sprint Bioscience AB's current Accounts Payable is kr2.4 Mil. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Accounts Payable compare to VRTX and REGN?
Sprint Bioscience AB's Accounts Payable of kr2.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sprint Bioscience AB and its competitors. Sprint Bioscience AB's current Accounts Payable is kr2.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr3.86 — trading 77.1% above its estimated fair value. The current Accounts Payable is kr2.4 Mil. Sprint Bioscience AB's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Accounts Payable is kr2.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of kr3.86 is trading 77.1% above its estimated GF Value™ of kr2.18. GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPRINT:

  • Accounts Payable: kr2.4 Mil
  • GF Value™: kr2.18 vs. price of kr3.86 (77.1% above fair value)
  • GF Score™: 32/100 with 1 warning sign

No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for OSTO:SPRINT

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.86
Price
kr2.18
GF Value